Observational analyses and post-hoc evaluations of major CV outcome trials, including DECLARE-TIMI and DAPA-HF, consistently show lower AF event rates among patients receiving SGLT-2 inhibitors. This evidence concerns the gene SLC5A2 and hydrops fetalis.